Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesGeisinger Health PlanGeisinger Health Plan Absorbable Hydrogel Spacer C…
    Ask Trek AI about this page
    CurrentGeisinger Health PlanPolicy MP320

    Absorbable Hydrogel Spacer

    Customize your policy alerts

    Sign up for Geisinger Health Plan Policy MP320 alerts

    Get alerted when Policy MP320 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Policy governing coverage of FDA‑approved absorbable rectal hydrogel spacers (e.g., SpaceOAR) to reduce rectal and urinary toxicity for men undergoing radiotherapy for prostate cancer; applies to Geisinger Health Plan lines of business per member benefit documents.

    Policy Summary
    PayerGeisinger Health Plan
    PolicyAbsorbable Hydrogel Spacer
    Policy CodePolicy MP320
    Change TypeNo material change
    Effective DateJul 18, 2024
    Last ReviewJul 18, 2025
    Next Review Date
    Key ActionVerify member eligibility and consult the member's contract and Geisinger prior authorization resources to determine if prior authorization is required.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    1associated procedural code listed
    Commercial/Medicare/Medicaidlines of business
    Annualpolicy reviewed at least
    may applyauthorization note

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Coverage Criteria for Absorbable Hydrogel Spacer

    Indications for Coverage

    Covered when ALL of the following are met

    Indication: Placement of an FDA-approved absorbable rectal hydrogel spacer is for reduction of rectal and urinary toxicity in men with prostate cancer undergoing radiotherapy.

    Explicitly limited to men with prostate cancer receiving radiotherapy per policy indications.

    Use of absorbable hydrogel spacers outside the indications listed in this policy is considered unproven and is therefore NOT COVERED. There is insufficient evidence in the peer‑reviewed literature to establish effectiveness of these spacers for indications other than those specified in this policy.

    Coverage for experimental or investigational treatments, services, and procedures is specifically excluded under the member's certificate with Geisinger Health Plan. This policy does not expand coverage to items or services that are excluded by the member's benefit document; see MP015 Experimental, Investigational or Unproven Services for additional information.

    Unproven services provided outside of an approved clinical trial are specifically excluded (not covered) under the member's certificate with Geisinger Health Plan. Prior authorization and pre‑certification requirements may still apply per the member’s contract and the Geisinger provider clinical policies web page.

    Associated Procedure and Billing Codes

    Associated CPT/HCPCS CodesCPT
    55874Transperineal placement of biodegradable material, peri-prostatic, single or multiple injection(s), including image guidance, when performed

    Provider Actions, Prior Authorization, and Billing Notes

    Prior Authorization

    Prior authorization & coding note — CPT 55874; verify member benefits

    Procedure code 55874 (Transperineal placement of biodegradable material, peri-prostatic, single or multiple injection(s), including image guidance, when performed) is listed in the coding section; coverage and reimbursement are determined by the member-specific benefit plan document and any applicable laws or Medicare rules.

    • 55874 — Transperineal placement of biodegradable material, peri-prostatic, single or multiple injection(s), including image guidance, when performed
    • Inclusion of a code does not guarantee coverage or reimbursement; verify member benefits.
    Prior Authorization

    Prior authorization may be required — consult member contract and Geisinger resources

    Prior authorization and/or pre‑certification may be required for this service; providers must consult the member's contract and the Geisinger provider clinical policies site for specific prior authorization requirements.

    • Check the member-specific contract/benefit document for precertification lists.
    • Prior authorization requirements are posted at the Geisinger provider clinical policies web page.
    Step Therapy

    Step therapy — none specified in policy

    No step therapy requirements are specified in this policy; applicability of any utilization management requirements depends on the member benefit document and, for Medicare members, applicable LCDs/NCDs.

    • Verify any additional requirements in the member's benefit document and applicable Medicare LCD/NCD.
    Documentation Required

    Verify eligibility and contract-specific benefits; LOB documents supersede policy

    Coverage is limited to the policy indication and to members meeting eligibility and contract‑specific benefits; line‑of‑business benefit documents supersede this policy and Medicare LCDs/NCDs will supersede the policy for Medicare members.

    • Verify member eligibility and contract-specific benefits, limitations, and exclusions before ordering.
    • For Medicare members, confirm applicable LCD/NCDs.
    Documentation Required

    Coverage subject to eligibility and contract limitations

    Coverage is subject to member eligibility and contract-specific benefits, limitations, and exclusions; benefits found in line‑of‑business documents supersede this policy.

    • Confirm benefits, limitations, or exclusions in the member's contract prior to scheduling the procedure.
    Note

    Prior authorization and precertification sources — where to find requirements

    Precertification lists and prior authorization requirements may apply and are located in the member's contract-specific benefit document and on the Geisinger provider clinical policies web page.

    • Precertification lists: member's contract-specific benefit document.
    • Prior authorization requirements: https://www.geisinger.org/health-plan/providers/ghp-clinical-policies
    Denial Risk

    Requests for hydrogel spacer use outside listed indication — considered unproven/NOT COVERED

    Requests to use absorbable hydrogel spacers for indications outside those listed in this policy (i.e., other than men with prostate cancer undergoing radiotherapy) are considered unproven and are NOT COVERED; such requests may be denied.

    • Use outside listed indications is considered unproven due to insufficient evidence in peer‑reviewed literature.
    • Do not expect approval for non‑listed indications without supporting evidence or an approved clinical trial.
    Denial Risk

    Exclusion triggers — experimental/investigational or unproven services excluded

    Coverage for experimental or investigational treatments, services, and procedures — and unproven services outside an approved clinical trial — are specifically excluded under the member's certificate and may trigger denials.

    • This policy does not expand coverage to services/items specifically excluded in the member's certificate.
    • See MP015 for additional information on experimental/investigational/unproven services.

    Clinical Background

    Absorbable hydrogel spacers are an injectable polyethylene glycol‑based hydrogel placed between the prostate and rectum under ultrasound guidance to increase separation and reduce rectal radiation dose during prostate radiotherapy. The polymer typically solidifies within seconds, remains in place for approximately 3 months during radiotherapy, and then hydrolyzes and is eliminated.

    Definitions

    inv-15: Absorbable hydrogel spacer — definition and key properties
    DefinitionInjectable polyethylene glycol–based hydrogel administered under ultrasound guidance that expands the space between the prostate and rectal wall and solidifies into a soft, firm gel within ~10 seconds.
    Duration in placeRemains in place for approximately 3 months during radiotherapy before hydrolyzing, liquefying and being absorbed and cleared in the urine.
    PurposeIntended to reduce unintentional rectal toxicity (and associated urinary toxicity) during radiotherapy for prostate cancer in men.
    AdministrationDelivered as a liquid injection with ultrasound guidance to create separation between prostate and rectum.
    Physical behaviorPolymerizes/solidifies rapidly (within ~10 seconds) into a soft but firm hydrogel that later hydrolyzes and is excreted.
    inv-16: Absorbable perirectal hydrogel spacer — polyethylene glycol-based biodegradable hydrogel (e.g., SpaceOAR)
    DescriptionA polyethylene glycol–based biodegradable perirectal hydrogel (example: SpaceOAR) injected between the prostate and rectum to increase separation and reduce rectal radiation dose during prostate radiotherapy.
    Example productSpaceOAR (polyethylene glycol–based perirectal hydrogel) cited in the policy and literature references as the prototype device evaluated in trials and assessments.
    Clinical effectImproves rectal dosimetry and is associated with reduced late gastrointestinal toxicity in published trials and systematic reviews referenced by the policy.
    BiodegradationBiodegradable: remains in place through the radiotherapy course (~3 months) then hydrolyzes and is cleared via urine, per product behavior described in the policy.
    Evidence baseSupported by phase II/III trials and health technology assessments cited in the policy references (see listed studies and Hayes assessment).
    Policy Summary
    PayerGeisinger Health Plan
    PolicyAbsorbable Hydrogel Spacer
    Policy CodePolicy MP320
    Change TypeNo material change
    Effective DateJul 18, 2024
    Last ReviewJul 18, 2025
    Next Review Date
    Key ActionVerify member eligibility and consult the member's contract and Geisinger prior authorization resources to determine if prior authorization is required.
    SourceLink
    On This Page
    Coverage Criteria for Absorbable Hydrogel SpacerAssociated Procedure and Billing CodesProvider Actions, Prior Authorization, and Billing NotesClinical BackgroundDefinitions